Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Shuzhen Chen

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4881-0558; OpenAlex author ID A5038588938. Sources: OpenAlex.

Their work

Papers
3 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
1
Collaborators
5
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 1 paper

Papers 3

  1. Application of small interfering RNAs and drug combination for pancreatic cancer therapy. First author DOI 10.1080/1061186x.2026.2663993↗
  2. YKL-06-061 exerts antitumor effect through G1/S phase arrest by downregulating c-Myc and inhibition of metastasis via SIK1 upregulation in pancreatic cancer. Last author DOI 10.1097/cad.0000000000001673↗
  3. A Macropinocytosis-Intensifying Albumin Domain-Based scFv Antibody and Its Conjugate Directed against K-Ras Mutant Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.8b00234↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chaoyang Zeng · 1 shared paper, 2026 · strength 0.63
  2. Chao-Yang Zeng · 1 shared paper, 2025 · strength 0.30
  3. Weijin Sheng · 1 shared paper, 2018 · strength 0.08
  4. Xiaofei Wang · 1 shared paper, 2018 · strength 0.08
  5. Yong‐Su Zhen · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.